Marengo Therapeutics

Monoclonal Antibodies

CO-STAR Clin0 solid tumors; STAR002 Clin0 solid tumors; STAR003 Clin0 solid tumors; TRI-STAR001 RD cold tumors; SKAR001 RD cold tumors

Marengo Therapeutics is pioneering a new way to activate the body’s own immune system to treat disease. The mission of Marengo is to activate the right immune cells to promote lifelong protection against cancer. Using their understanding of T-cell receptor (TCR) biology, Marengo is designing therapies to activate a subset of T-cells known as tumor-infiltrating lymphocytes. With their versalite antibody technology platform, Marengo can modulate this subset of T-cells in different ways to support the rapid development of clinic-ready therapeutics for various diseases. Marengo’s lead candidate, START-001, is already in clinical trials for advanced antigen-rich solid tumors.